Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALANASDAQ:EVLONASDAQ:HSTONYSE:NAVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00$0.00▼$0.05$10K-2.5616,732 shs5 shsEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.06$9K0.7414,287 shs10 shsHSTOHistogen$0.00-8.3%$0.03$0.05▼$0.55$5K1.1910,369 shs2,653 shsNAVBNavidea Biopharmaceuticals$0.00$0.00$0.00▼$0.13$70K1.79,050 shs10,524 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%0.00%+1,900.00%+233.33%-90.00%EVLOEvelo Biosciences0.00%0.00%+66.67%0.00%-16.67%HSTOHistogen-8.33%-96.33%-96.62%-96.33%-99.39%NAVBNavidea Biopharmaceuticals0.00%0.00%-93.00%+600.00%+600.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALACalithera Biosciences0.5882 of 5 stars0.01.00.04.50.60.00.0EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/AHSTOHistogen 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AHSTOHistogen$19K0.25N/AN/A$3.13 per share0.00NAVBNavidea Biopharmaceuticals$8.13K8.62N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/AEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A7/7/2025 (Estimated)HSTOHistogen-$10.62M-$2.81N/A∞N/AN/AN/AN/AN/ANAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/AEVLOEvelo Biosciences0.31%HSTOHistogenN/ANAVBNavidea Biopharmaceuticals0.01%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%EVLOEvelo Biosciences1.02%HSTOHistogen3.30%NAVBNavidea Biopharmaceuticals43.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataHSTOHistogen204.27 millionN/ANot OptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableEVLO, HSTO, NAVB, and CALA HeadlinesRecent News About These CompaniesNavidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock SplitMay 21, 2025 | businesswire.comNavidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax AssetsMarch 31, 2025 | businesswire.comNavidea Biopharmaceuticals Inc. (NAVB) Latest Pre Market TradesDecember 23, 2024 | nasdaq.comNavidea Biopharmaceutical (OTC:NAVB) Stock Quotes, Forecast and News SummaryOctober 28, 2024 | benzinga.comNavidea Biopharmaceuticals gets grant for treatment of flaviviridae family virus infectionsAugust 23, 2024 | pharmaceutical-technology.comNavidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024July 3, 2024 | businesswire.comNavidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024June 20, 2024 | businesswire.comSK Biopharmaceuticals Co. Ltd.May 25, 2024 | wsj.comDay One Biopharmaceuticals, Inc. Common Stock (DAWN)May 3, 2024 | nasdaq.comNavidea Biopharmaceuticals files patent for polymeric compound for treating diseases involving macrophagesMarch 6, 2024 | pharmaceutical-technology.comNavidea Biopharmaceuticals gets grant for method for conjugating metal chelating agent to functionalized dextranMarch 5, 2024 | pharmaceutical-technology.comNavidea Biopharmaceutical Stock (OTC:NAVB), Short Interest ReportFebruary 23, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB) Insider TradesFebruary 22, 2024 | benzinga.comCentral Ohio public company voluntarily deregisters stockJanuary 29, 2024 | bizjournals.comNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting ObligationsJanuary 26, 2024 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting ObligationsJanuary 26, 2024 | finance.yahoo.comSuzhou Zelgen Biopharmaceuticals Co Ltd (688266)January 11, 2024 | investing.comNavidea settles litigation with Capital Royalty, stock rallies 30%December 1, 2023 | msn.comNavidea Biopharmaceuticals, CRG Settle All Ongoing LitigationDecember 1, 2023 | markets.businessinsider.comMedia Sentiment Over TimeEVLO, HSTO, NAVB, and CALA Company DescriptionsCalithera Biosciences NASDAQ:CALA$0.0020 0.00 (0.00%) As of 06/11/2025Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Evelo Biosciences NASDAQ:EVLO$0.0005 0.00 (0.00%) As of 06/11/2025Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Histogen NASDAQ:HSTO$0.0011 0.00 (-8.33%) As of 06/10/2025Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.Navidea Biopharmaceuticals NYSE:NAVB$0.0007 0.00 (0.00%) As of 02:33 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
